Multicenter evaluation of the addition of eltrombopag to immunosuppressive therapy for adults with severe aplastic anemia.

Autor: Shinn LT; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Benitez LL; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Perissinotti AJ; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Reid JH; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA., Buhlinger KM; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA., van Deventer H; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA., Barth D; Department of Pharmacy, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Wagner CB; Department of Pharmacy, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Zacholski K; Department of Pharmacy, Virginia Commonwealth University Medical Center, Richmond, VA, USA., Desai R; Department of Pharmacy, Virginia Commonwealth University Medical Center, Richmond, VA, USA., Soule A; Department of Pharmacy, University of Kentucky HealthCare, Lexington, KY, USA., Stump SE; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weis TM; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bixby D; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Burke P; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Pettit K; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA., Marini BL; Department of Clinical Pharmacy, Michigan Medicine and University of Michigan College of Pharmacy, 1540 E. Hospital Dr., Room 251-B, Ann Arbor, MI, USA. bernmari@med.umich.edu.

Publikováno v: International journal of hematology [Int J Hematol] 2023 Dec; Vol. 118 (6), pp. 682-689. Date of Electronic Publication: 2023 Oct 26.

Real-world analysis of the safety/tolerability of gilteritinib in combination with mold-active azole prophylaxis.

Autor: King AC; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Derkach A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weis TM; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Stump SE; Department of Pharmacy, Clinical Programs, Vanderbilt University Medical Center, Nashville, TN, USA., Ciervo JR; Department of Pharmacy, Clinical Programs, Memorial Sloan Kettering Cancer, New York, NY, USA., Ranaghan CP; Department of Nursing, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stein ES; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: steine@mskcc.org.

Publikováno v: Leukemia research [Leuk Res] 2022 Nov; Vol. 122, pp. 106929. Date of Electronic Publication: 2022 Sep 06.

Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.

Autor: Collins J 4th; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Stump SE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Heiling H; UNC Lineberger Cancer Center, Chapel Hill, NC, USA., Muir M; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.; GlaxoSmithKline, Research Triangle Park, NC, USA., Deal A; UNC Lineberger Cancer Center, Chapel Hill, NC, USA., Proco D; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.; GlaxoSmithKline, Research Triangle Park, NC, USA., Nguyen C; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Cozad M; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA., Mato A; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Coombs CC; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., Muluneh B; UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.; UNC Lineberger Cancer Center, Chapel Hill, NC, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1823-1830. Date of Electronic Publication: 2022 Mar 06.

Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia.

Autor: Ochs MA; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA., Marini BL; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; University of Michigan College of Pharmacy, Ann Arbor, MI, USA., Benitez LL; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.; University of Michigan College of Pharmacy, Ann Arbor, MI, USA., Stump SE; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Weis TM; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Buhlinger KM; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA., Diaz T; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA., Reid JH; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA., Muluneh B; Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.; University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, USA., Pettit K; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA., Burke P; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA., Bixby DL; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, Ann Arbor, MI, USA., Perissinotti AJ; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, Ann Arbor, MI, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2022 Aug; Vol. 63 (8), pp. 1839-1848. Date of Electronic Publication: 2022 Mar 28.

A JAK2/IDH1-mutant MPN clone unmasked by ivosidenib in an AML patient without antecedent MPN.

Autor: Xiao W; Hematopathology Service, Department of Pathology.; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Miles LA; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Bowman RL; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Durani V; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Tian HS; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., DelGaudio NL; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Mishra T; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program., Zhu M; Diagnostic Molecular Pathology, Department of Pathology., Zhang Y; Cytogenetics Laboratory, Department of Pathology., Stump SE; Leukemia Service, Department of Pharmacy, and., Tallman MS; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Levine RL; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Cai SF; Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Publikováno v: Blood advances [Blood Adv] 2020 Dec 08; Vol. 4 (23), pp. 6034-6038.